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A b s t r a c t
Background: The KCNQ1 and HERG genes mutations are responsible for specific types of congenital long QT syndrome (LQT).
Aim: To examine the expression of KCNQ1 and HERG genes that encode potassium channels (rapid and slow) responsible
for the occurrence of particular types of LQT syndrome. The study also attempted to prove that beta-actin is a good endoge-
nous control when determining the expression of the studied genes.
Methods: The study enrolled six families whose members suffered from either LQT1 or LQT2, or were healthy. Examination
of gene expression was achieved with quantitative PCR (QRT-PCR). Expression of the investigated genes was inferred from
the analysis of the number of mRNA copies per 1 mg total RNA isolated from whole blood. On the basis of KCNQ1 gene
expression profile, the presence of, or absence of, LQT1 could be confirmed.
Results and conclusions: The study revealed a statistically significant difference (p = 0.031) between the number of KCNQ1
gene copies in patients and healthy controls. On the basis of HERG (KCNH2) gene expression profile, patients with LQT2
cannot be unequivocally differentiated from healthy subjects (p = 0.37).
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INTRODUCTION
Congenital long QT syndrome (LQT) is a disorder of ion chan-
nels characterised by long QT interval (> 450 ms) on ECG,
occurrence of polymorphic ventricular tachycardia (torsade
de pointes), fainting and sudden cardiac death (SCD) [1]. To
date, mutations in 11 genes have been discovered and de-
scribed as being relevant for this disease. The most frequent
are mutations in KCNQ1, HERG (KCNH2) and SCN5A genes
which are responsible for the Romano-Ward, Jervell and Lange-
-Nielsen as well as Brugada syndromes [2]. Clinical symptoms
depend on the gene affected by mutation and on individual
predisposition [3–5].
The LQT1 type may be caused by mutation in the
KCNQ1 gene and is found in approximately 50–60% of ca-
ses. Romano-Ward syndrome is an autosomal dominant he-
reditary disease found in around 99% of LQT1 cases. Jervell
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and Lange-Nielsen syndrome is an autosomal recessive here-
ditary disease of much rarer occurrence (approximately 1%).
Its characteristic features are congenital hearing loss and re-
current syncope, with a high risk of SCD in childhood [6, 7].
Symptoms are usually triggered by excitation of the b-adre-
nergic system through increased physical effort (mainly swim-
ming) or through strong emotions such as stress, anxiety or
fright. Women diagnosed with LQT during their puerperium
are in categories with the highest rate of lethal cardiac events
[8, 9]. LQT1 has a unique ECG pattern characterised by a long
QT interval (above 450 ms) and characteristic T wave mor-
phology, which may have a wide base, increase slowly or have
a delayed start [6].
The KCNQ1 is mapped to chromosome band 11p15.5.
It comprises 16 exons (15 to 19 as the result of alternative
splicing) spanning approximately 400 kB [10]. The gene en-
codes a protein forming the subunit a of the transmembrane
slow potassium channel (IKs), consists of 676 aminoacids; with
shorter isomorph 549 aminoacids in the heart [10]. In hu-
mans, KCNQ1 gene is expressed in the kidneys, placenta,
lungs and heart. Highest mRNA transcript levels of KCNQ1
gene have been observed in heart muscle cells; no expres-
sion has been found in the brain, skeletal muscles or liver [6].
The LQT2 type can be caused by mutations in the HERG
(KCNH2) gene and is found in 30–35% of clinical cases. It is
an autosomal dominant hereditary disorder manifesting itself
as Romano-Ward syndrome. The LQT2 can be triggered by
strong auditory stimuli such as doorbells, phones ringing, si-
rens or alarm clocks; it may also occur under the influence of
excessive catecholamine secretion [5, 11, 12]. The ECG shows
a long QT interval (above 450 ms) and discernible T wave
with low amplitude and biphasic overlapping on the descen-
ding arm [5, 13, 14].
The HERG (KCNH2) gene, mapped to chromosome
7q35-36, consists of 15 exons (total approximately 19 kB).
The corresponding protein product, consisting of 1,159 ami-
noacids, forms the a subunit of IKr rapid potassium channel
[15, 16], mRNA for HERG gene is found primarily in heart
muscle cells. KCNH2 gene has been shown to be important
in preventing premature heart stimulation [17, 18].
The principal goal of our study was to examine the expres-
sion of KCNQ1 and HERG genes encoding potassium chan-
nels that are responsible for the occurrence of LQT1 and
LQT2. The study aimed also at the confirmation of LQT among
family members of patients diagnosed with this disease. Ad-
ditionally, the study attempted to answer as to whether and
how the expression of the examined genes changes in sub-
jects with clinically diagnosed LQT. Lastly, we sought to veri-
fy whether b-actin is a good endogenous control for determi-
ning the expression of the studied genes.
METHODS
Gene expression was studied in subjects from six unrelated
families. Initial diagnoses were based on such clinical featu-
res as altered ECG parameters, personal and family history of
syncope and arrhythmia and/or aborted SCD. In total, 23 pa-
tients with clinically diagnosed LQT were enrolled in the stu-
dy; 12 patients with LQT1 and 11 patients with LQT2. The
remaining 21 were healthy individuals without clinically con-
firmed LQT symptoms. Consent to use blood samples taken
from patients was obtained from the Bioethics Committee of
the Medical University of Silesia.
Total RNA extraction
Total RNA extraction was performed using Fenozol total RNA
isolation Reagent Set (A&A Biotechnology) ready-to-use.
Quantitative RT-PCR
Assessment of the transcriptional activity of the investigated
genes was carried out using commercial kits (TaqMan Gene
Expression Assays Applera for KCNQ1 gene 4331182
Hs00165003m1; for HERG gene 4331182 Hs00542478m1)
5’ end-labelled with FAM and 3’ end-labelled with non-
fluorescent quencher. The number of mRNA copies of the
investigated genes (KCNQ1, HERG, b-actin) was determined
based on kinetics of the QRT-PCR reaction using ABI PRISM™
7000 sequence detector (Applied Biosystems, CA, USA) and
ROX QuantiTect Probe RT-PCR kit containing a fluorescent
dye. The QRT-PCR was carried out in one step. The reaction
mix contained: 10 mL 2 × QuantiTect Probe RT-PCR Master
Mix (HotStarTaq DNA Polymerase, QuantiTect Probe RT-PCR
buffer containing Tris-HCl, KCl, (NH4)2SO4, 8 mm MgCl2,
pH = 8.7, dNTP mix and ROX reference dye) and 0.1 mL
QuantiTect RT Mix (QuantiTect Probe RT-PCR kit, Qiagen
GmbH, Germany) and 1 mL mix of TaqMan Gene Expression
Assay starters and probes (Applied Biosystems), RNA matrix
and pyrogen-free water. The reaction mix to amplify b-actin
gene DNA standards contained: 25 mL 2 × QuantiTect Probe
RT-PCR Master Mix (HotStarTaq DNA Polymerase, Quanti-
Tect Probe RT-PCR containing Tris-HCl, KCl, (NH4)2SO4,
5 mm MgCl2, pH = 8.7, dNTP mix, reference ROX) (Qiagen
GmbH, Germany) and 0.5 mm sense and antisense starters,
b-actin cDNA template and pyrogen-free water. (Applied Bio-
systems TaqMan Gene Expression Assays for AKT 4331182
Hs 99999903_m1).
The reverse transcription reaction (in two repeats) was
carried out at 50°C for 30 min. Following initial activation of
HotStar Taq DNA polymerase (95°C/15 min) a two-step re-
action was carried out: denaturation at 94°C for 15 s, and
starter annealing at 60°C for 60 s (40 cycles). Final elongation
of amplification products was carried out at 72°C for 10 min.
A series of QRT-PCR reactions was performed. The electro-
phoretic analysis of amplimers (length of PCR product for
KCNQ1 gene — 78 bp; for HERG gene — 82 bp) and sequence
analysis confirmed the specificity of the performed QRT-PCR
reaction (data not shown). The results are expressed as the
number of mRNA copies of the analysed genes per 1 mg of
total RNA.
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Statistical analysis
Data was exported from an Excel datasheet to Statistica v.7.1.
data analysis software system (StatSoft Inc. 2006). Due to the
lack of normal distribution of the investigated parameters (exa-
mined with Shapiro-Wilk test) we used a non-parametric
Mann-Whitney U-test to analyse the results from the experi-
mental and control groups. Correlation between mRNA copy
numbers and clinical parameters was analysed using Spear-
man rank test correlation. The statistical significance level was
set at p < 0.05.
RESULTS
Among three families with LQT1 were three asymptomatic
mothers and nine children (8 ± 0.5 years), all with typical
triggers of cardiac events (exercise and emotional stress). In
three families with LQT2 were five adults and six children
(7 ± 0.5 years). Three (50%) children and two mothers were
symptomatic, triggered by stress, auditory stimuli or during
rest or sleep. The twin-mothers with LQT2 presented with
recurrent syncope during pregnancy and puerperium, and
they had an implanted cardioverter-defibrillator. Their chil-
dren were younger (3 ± 0.5 years) and without any symp-
toms. In the standard ECG, the duration of QT corrected using
Bazett’s formula (QTc) was significantly longer in the LQT2
group (median 0.48) compared to the LQT1 (median 0.4),
p = 0.000082 (Table 1).
No significant difference was noted between the num-
ber of mRNA copies of KCNQ1 gene in patients diagnosed
with LQT1 as against LQT2. Similar results were obtained
when numbers of mRNA copies were compared for KCNH2
gene in the LQT1 and LQT2 patients. No significant differen-
ce between expression levels was revealed. Endogenous con-
trol was chosen correctly, as expression levels of the control
gene (b-actin) did not differ in both investigated groups
(Table 2).
We found a significant difference between the number
of mRNA copies of KCNQ1 gene in LQT1 patients and con-
trols (p = 0.031). Comparison of expression levels of LQT1
patients and controls for KCNH2 gene revealed no significant
differences because there is no candidate gene for this type
of LQT (Table 2).
Comparison of expression levels of LQT2 patients and
controls for KCNH2 and KCNQ1 genes revealed no signifi-
cant differences (Table 2). Endogenous control was chosen
correctly, as expression levels of the control gene (b-actin)
did not differ in both investigated groups (p = 0.66).
Differences in expression levels of KCNQ1 gene in pa-
tients with both types of syndrome and in controls were of
borderline significance (p = 0.053). For the KCNH2 gene, no
significant differences were revealed between the two groups
(Table 2).
We did not find any significant correlation between
KCNQ1 and KCNH2 mRNA copy numbers and QTc in pa-
tients with LQT1. We found a negative correlation between
KCNQ1 mRNA copy numbers and QTc in patients with LQT2
(p < 0.05; r = –0.73). We did not find any correlation be-
tween KCNH2 mRNA copy numbers and QTc in patients
with LQT2 (p > 0.05).
We found that symptomatic patients had a significantly
higher KCNQ1 mRNA copy number than asymptomatic ones
(p = 0.05). There were no differences beetween KCNH2
mRNA copy numbers in the analysed groups. We observed
a trend towards higher expression of KCNH2 in symptomatic
patients versus asymptomatic ones (NS).
DISCUSSION
Our study documented a different expression level of KCNQ1
gene in patients with LQT1 and in healthy controls. The other
working hypothesis concerning different expression of KCNH2
gene in patients with LQT2 and in healthy individuals was
not confirmed, possibly due to the numbers of patients and
controls being too small. It is also possible that the disease
was not yet expressed at such a young age (most symptoma-
tic patients are young children), and that the molecular expres-
sion of LQT syndrome was different, depending on the num-
ber of mRNA copies.
To the best of our knowledge, the results described he-
rein have not been reported previously. Published studies have
concentrated on a RT-PCR investigation of KCNQ1 and HERG
expression levels using mRNA isolated from horse heart mu-
scle (vestibular and ventricular cells) [19]. These studies do-
cummented different expression levels of the studied genes
in these two particular types of cells. The expression levels
found in horse heart cells were similar to those found in rat
and ferret. Finley et al. [19] also studied protein products of
the genes in question, using antibodies directed against
C-terminal epitope fragments.
Franco et al. [20] reported discrepant data concerning
the expression of genes that encode potassium channels, at
particular stages of murine heart embryonal development.
Expression for the studied genes was analysed from the stage
of tubular heart development until the full separation of ven-
tricles. At the initial stages, KCNQ1 gene was shown to be
expressed at similar levels in all elements of the heart. Expres-
sion at comparable level was sustained until the foetal stage
of development characterised by full separation of ventricles;
elevated expression was found only at the late foetal period.
Investigation of another gene, HERG, revealed similar resuls
as for KCNQ1.
Lou et al. [21] studied KCNQ1 and HERG expression
levels and distribution in tissues, as well as commercially ava-
ilable cell lines (human embryonal kidney cells, heart muscle
cells, breast and prostate cancer cells). High levels of expres-
sion were confirmed in cells isolated from the heart, pancre-
as and colon, whereas those in skeletal muscles and breast
cancer cells were low. Elevated expression levels of both ge-
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Table 1. Clinical data of studied patients
Genotype/control Age [years] Gender QTc [s] Bazett’s formula Cardiac events/triggers
LQT-1 2 Male 0.53 Palpitations, fainting/stress
LQT-1 0.33 Male 0.48 Cardiac arrest/ICD
LQT-1 6 Male 0.46 Palpitations, fainting/exercise
LQT-1 15 Female 0.47 Palpitations, fainting
LQT-1 4 Female 0.46 Palpitations, fainting
LQT-1 32 Female 0.48
LQT-1 10 Female 0.46 Syncope/exercise
LQT-1 46 Female 0.46
LQT-1 7 Male 0.47 Fainting/exercise
LQT-1 16 Female 0.50 Fainting/exercise
LQT-1 37 Female 0.48
LQT-1 15 Female 0.48 Palpitations
Control-LQT1 13 Female 0.42
Control-LQT1 43 Male 0.39
Control-LQT1 23 Male 0.38
Control-LQT1 11 Female 0.39
Control-LQT1 52 Male 0.4
Control-LQT1 74 Female 0.40
Control-LQT1 41 Female 0.32
Control-LQT1 53 Male 0.40
Control-LQT1 22 Female 0.44
Control-LQT1 47 Male 0.39
Control-LQT1 41 Male 0.40
LQT-2 2 Male 0.48
LQT-2 3 Female 0.48
LQT-2 21 Female 0.55 Palpitations, recidivans syncope/puerperium/ICD
LQT-2 21 Female 0.54 Syncope-arousal/puerperium/ICD
LQT-2 4 Female 0.49 Fainting-stress/absence
LQT-2 6 Male 0.46 Syncope-stress-at rest, night
LQT-2 50 Female 0.53
LQT-2 29 Male 0.46
LQT-2 16 Female 0.46 Syncope-stress
LQT-2 11 Female 0.46
LQT-2 39 Female 0.46
Control-LQT2 22 Male 0.43
Control-LQT2 30 Male 0.4
Control-LQT2 5 Female 0.43
Control-LQT2 28 Female 0.44
Control-LQT2 27 Male 0.38
Control-LQT2 30 Female 0.39
Control-LQT2 55 Male 0.44
Control-LQT2 44 Male 0.43
Control-LQT2 65 Female 0.41
Control-LQT2 19 Female 0.41
ICD — implantable cardioverter-defibrillator
nes were found in the right atrium and ventricle compared to
the left atrium and ventricle, thus underlining differences in
expression levels in individual cardiac chambers.
The distinctive character of this study results from com-
paring the expression levels of KCNQ1 and KNCH2 genes in
subjects with clinically diagnosed LQT1 and LQT2 and in
healthy subjects. We found that symptomatic patients with
LQT1 have a significantly higher KCNQ1 mRNA copy num-
ber than asymptomatic ones. It is possible that in the long
QT1 type of syndrome, mRNA copy number is related to the
www.kardiologiapolska.pl
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occurrence of disease. We observed a trend towards
a higher expression of KCNH2 in symptomatic patients with
LQT2 vs asymptomatic ones, but that difference did not re-
ach statistical significance, presumably due to the limited
number of subjects.
The present study is also the first to use patients’ peri-
pheral blood as the material for the subject investigation. Stu-
dies on KCNQ1 and HERG expression reported thus far have
been based on animal biopsy material or commercially availa-
ble cell lines. On the basis of results obtained herein, the ef-
fects of KCNQ1 and HERG expression levels on the occurren-
ce of LQT cannot be unequivocally determined.
Detailed analysis of this problem would require further
studies involving larger study groups. This would permit a more
precise determination of gene expression levels at a popula-
tion level and would minimise statistical errors. It seems wor-
thwhile to compare expression levels of KCNQ1 and KCNH2
genes in myocyte biopsy specimens from subjectswith dia-
gnosed LQT and from healthy subjects. Cardiomyocytes may
prove to be the best study material available because of the
direct relationship between the functioning of ion channels
in the heart and the occurrence of LQT. However, in the light
of the results obtained herein, it could be that gene expres-
sion profiles are an additional criterion of differential diagno-
sis of long QT types. At present, this is an experimental me-
thod helpful in LQT diagnosis.
Our results allow a better LQT diagnosis to be obtained,
and, possibly, differentiation between its two commonest
phenotypes (LQT1 and LQT2). This would lead to a more
targeted therapy and prophylaxis, both of which are highly
desirable given the deadly nature of this syndrome.
Limitations of the study
The main possible limitation of our study is the fact that
gene expression changes are controlled through highly com-
plex, non-linear interactions between proteins, DNA, RNA,
and a variety of metabolites. Real-time PCR gene expres-
sion analysis measures mRNA levels and this method may
only suggest possible changes in protein levels or function
rather than demonstrate them. Protein expression may not
correlate with mRNA expression. Therefore, although there
is a close association between gene expression and protein
function, further analysis (e.g. protein analysis) will be ne-
cessary to clarify the role of KCNQ1 and KCNH2 expres-
sion level in LQT aetiology.
Another limitation is that the gene of interest must be
transcribed at detectable levels in available tissue samples.
Myocardial biopsy is not routinely performed for LQT dia-
gnosis. The Unigene National Centre for Biotechnology In-
formation and Gene Expression Omnibus suggest that
expression of KCNQ1 and KCNH2 genes is largely restric-
ted to the myocardium, and their mRNA transcripts can-
not be reliably obtained from lymphocyte cultures. On the
other hand, Miller et al. [22] showed that cardiovascular
restricted mRNAs can be readily detected in peripheral
blood without additional purification steps or cell culture,
and then used as the starting material for rapid high-fideli-
ty screening of mutations in genes associated with heart
diseases. Replication studies verifying our observations sho-
uld be performed.
CONCLUSIONS
1. KCNQ1 gene expression profile may be an additional
criterion for the presence of, or absence of, LQT1.
2. Patients with LQT2 cannot be unequivocally differentia-
ted from healthy controls on the basis of HERG (KCNH2)
gene expression profile.
3. Beta-actin may be of use as an endogenous control in
KCNQ1 and KCNH2 expression analysis in patients with
LQT.
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Table 2. Results of real-time PCR analysis for KCNQ1 and KCNH2 genes in long QT syndrome patients and healthy individuals
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S t r e s z c z e n i e
Wstęp i cel: Głównym celem pracy było zbadanie ekspresji genów HERG i KCNQ1, kodujących kanały potasowe (szybkie
i wolne), odpowiadających za wystąpienie określonego rodzaju zespołu długiego QT (LQTS).
Metody: Do badania włączono 6 rodzin, u członków których zdiagnozowano LQTS1 lub LQTS2, lub zdrowych. Badanie
miało na celu udowodnienie, że beta-aktyna stanowi dobrą kontrolę endogenną przy ustalaniu ekspresji badanych genów.
Do badania ekspresji genów wykorzystano ilościową analizę PCR w czasie rzeczywistym (QRT-PCR). Ekspresję badanych
genów przedstawiono jako liczbę kopii mRNA w przeliczeniu na 1 mg całkowitego RNA izolowanego z krwi pełnej. Dane
zostały wyeksportowane z arkusza Excel do programu analizy danych Statistica V.7.1.
Wyniki i wnioski: Na podstawie profilu ekspresji genu KCNQ1 można potwierdzić występowanie zespołu LQTS1. Badania
wykazały statystycznie istotną różnicę (p = 0,031) między liczbą KCNQ1 kopii genu u osób chorych i zdrowych. Na podstawie
profilu ekspresji genu HERG (KCNH2) chorych z LQTS2 nie można jednoznacznie odróżnić od osób zdrowych (p = 0,37).
Słowa kluczowe: zespół wydłużonego QT, KCNQ1, HERG, ekspresja genów
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